Andmed seisuga: 24.11.2024 23:09 (GMT+2)
VIISNURK
CASH FLOW STATEMENT
CONSOLIDATED CASH FLOW STATEMENT 01.01-31.12.99
in EEK, audited
1999 1998
Profit before taxes 26,077,512 18,288,557
Accumulated depreciation for the year 9,103,592 7,653,349
Profit from sale of securities -537,59 458,195
Profit from sale of shares in subsidiary -5,745,968 54,766
Profit/loss from sale of fixed assets 482,014 16,174
Profit from investments -186,256 -269,372
Interest expenses 2,737,310 4,183,883
Operating profit before changes in working capital 31,930,614 30,385,552
Change in current assets -1,501,100 -2,904,551
Change in current liabilities 7,922,329 1,611,951
Change in deferred income tax liabilities -2,859,137 345,963
Net cash flow from operating activities 35,492,706 29,438,915
Interest paid -3,029,928 -4,246,251
Income tax paid -1,198,306 -4,620,738
Net cash from operating activities 31,264,472 20,571,926
Investing activities
Purchase of fixed assets -37,034,682 -11,266,227
Disposal of fixed assets 582,399 123,827
Purchase of current investments -6,053,060 -252,123
Disposal of current investments 6,672,186 18,843
Purchase/disposal of shares in subsidiary 8,495,873 257,5
Interest received 86,083 167,312
Dividends received 100,173 102,06
Net cash used in investing activities -27,151,028 -10,848,808
Financing activities
Proceeds from issue of shares 0 1,152,190
Proceeds from long-term borrowings 9,026,370 2,250,000
Repayment of borrowings -14,030,041 -4,400,441
Finance lease payments -900,036 -1,599,633
Decrease of credit line balance 0 -4,253,419
Net cash used in financing activities -5,903,707 -6,851,303
Net change in cash -1,790,263 2,871,815
Cash and cash equivalents at beginning of period 4,736,585 1,864,770
Cash and cash equivalents at end of period 2,946,322 4,736,585
Andrus Aljas
Financial Director
+372 44 78 355